MiR-17-5p promotes cellular proliferation and invasiveness by targeting RUNX3 in gastric cancer

Jin Song,Yingjun Liu,Tianyuan Wang,Bo Li,Shengsheng Zhang
DOI: https://doi.org/10.1016/j.biopha.2020.110246
2020-08-01
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Dysregulated microRNAs (miRNAs/miRs) directly modulate the biological functions of gastric cancer (GC) cells and contribute to the initiation and progression of GC. MiR-17-5p and runt-related transcription factor 3 (RUNX3) have been reported to be related to GC progression; however, the specific interaction between miR-17-5p and RUNX3 in GC require further investigation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Western blotting, real-time PCR and immunohistochemistry were used to study the expression level of miR-17-5p and RUNX3 in gastric cancer tissues and plasma. The biological function of miR-17-5p was examined by measuring cell proliferation, apoptosis and cell invasion <em>in vitro</em>; the target gene of miR17-5p was identified by luciferase reporter assays, RNA Binding protein immunoprecipitation (RIP) and western blotting. <em>In vivo</em> animal study was conducted to confirm the role of miR-17-5p during tumorigensis of gastric cancer.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>This study showed that miR17-5p was upregulated in the plasma and tissues of patients with GC, while RUNX3 was downregulated in GC tissues. Functional experiments indicated that miR-17-5p mimics promoted the proliferation and invasion of GC <em>via</em> suppressing apoptosis <em>in vitro</em>. Furthermore, bioinformatics prediction, luciferase reporter assays, reverse transcription quantitative polymerase chain reaction assays, RIP and western blotting analysis demonstrated that RUNX3 was a direct target gene of miR-17-5p in GC. In addition, overexpression of RUNX3 suppressed the proliferation and invasiveness of GC cells. <em>In vivo</em> data indicated miR-17-5p agomir significantly promoted tumor growth. In contrast, miR-17-5p antagomir notably decreased tumor volume compared with control group.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>MiR-17-5p promoted the progression of GC <em>via</em> directly targeting RUNX3, suggesting that miR-17-5p and RUNX3 could be considered as diagnostic and therapeutic targets for patients with GC.</p>
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?